Adverse Events Module

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module

Ignite Creation Date: 2025-12-25 @ 3:18 AM
Ignite Modification Date: 2025-12-26 @ 1:57 AM
NCT ID: NCT02432105
Description: An AE was defined as any untoward medical occurrence in a participant who was administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. AEs were obtained through solicited and spontaneous comments from participants and through observations by the Investigator as outlined in the study protocol.
Frequency Threshold: 5
Time Frame: Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 19 days).This analysis population includes all participants who had tympanostomy tubes inserted and were randomized. AEs are reported as pre-treatment and treatment-emergent.
Study: NCT02432105
Study Brief: Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Pretreatment All AEs reported prior to randomization 0 None 1 470 7 470 View
EXE844 7 Days All participants treated with EXE844 Sterile Otic Suspension, 0.3% for 7 days after Tympanostomy Tube Insertion 0 None 1 164 27 164 View
EXE844 3 Days All participants treated with EXE844 Sterile Otic Suspension, 0.3% for 3 days after Tympanostomy Tube Insertion 0 None 1 110 21 110 View
Tubes Only All participants treated with bilateral myringotomy and tympanostomy tube insertion only 0 None 0 111 40 111 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Intussusception SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.0) View
Viral rash SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.0) View
Asthma SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (18.0) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Otorrhoea SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders MedDRA (18.0) View
Ear pain SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders MedDRA (18.0) View
Upper respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.0) View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.0) View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.0) View